Tralokinumab: Discovering the Possibility of LP 0162 and CAT-354 Tralokinumab, previously known as LP 0162 and CAT-354, represents a promising therapy for severe dermatitis. This monoclonal antibody inhibits https://www.targetmol.com/compound/tralokinumab